Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

出版年份 2019 全文链接

标题

作者

关键词

出版物

LANCET ONCOLOGY

Volume 20, Issue 7, Pages 961-971

出版商

Elsevier BV

发表日期

2019-06-03

DOI

10.1016/s1470-2045(19)30331-6

向作者/读者发起求助以获取更多资源

Protocol

在线求助

Reagent

在线求助

Reprint

联系作者

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started